Cargando…

Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort

Immune checkpoint blockade (ICB) induces a remarkable response in patients with certain cancers. However, the response rate is not yet satisfactory. Biomarkers that help physicians identify patients who would benefit from ICB need to be developed. Killer immunoglobulin-like receptors (KIRs) are a cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishida, Yoshihiro, Nakashima, Chisa, Kojima, Hiroto, Tanaka, Hidenori, Fujimura, Taku, Matsushita, Shigeto, Yamamoto, Yuki, Yoshino, Koji, Fujisawa, Yasuhiro, Otsuka, Atsushi, Kabashima, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206129/ https://www.ncbi.nlm.nih.gov/pubmed/30374122 http://dx.doi.org/10.1038/s41598-018-34044-z

Ejemplares similares

Variable indoleamine 2,3‐dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy
por: Iga, Natsuko, et al.
Publicado: (2019)

Accumulation of exhausted CD8+ T cells in extramammary Paget’s disease
por: Iga, Natsuko, et al.
Publicado: (2019)

Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
por: MUTO, Yusuke, et al.
Publicado: (2022)

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
por: Rerknimitr, Pawinee, et al.
Publicado: (2017)

Cutaneous angiosarcoma treated with taxane‐based chemoradiotherapy: A multicenter study of 90 Japanese cases
por: Fujimura, Taku, et al.
Publicado: (2022)

Editorial: Recent Developments in Therapies and Diagnostic Tools for Melanoma and Non-melanoma Skin Cancer
por: Fujimura, Taku, et al.
Publicado: (2020)

Cutaneous angiosarcoma: update on biology and latest treatment
por: Ishida, Yoshihiro, et al.
Publicado: (2018)

Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor
por: Fujisawa, Yasuhiro, et al.
Publicado: (2018)

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
por: Fujimura, Taku, et al.
Publicado: (2018)

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2019)

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
por: SAKAGUCHI, Yuri, et al.
Publicado: (2020)

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
por: Fujimura, Taku, et al.
Publicado: (2018)

Histidine‐rich glycoprotein augments natural killer cell function by modulating PD‐1 expression via CLEC‐1B
por: Nishimura, Yoshito, et al.
Publicado: (2019)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
por: Fujimura, Taku, et al.
Publicado: (2019)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
por: Ishii, Maki, et al.
Publicado: (2020)

Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer
por: Fujimura, Taku, et al.
Publicado: (2018)

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
por: Kambayashi, Yumi, et al.
Publicado: (2019)

Microclusters of inhibitory killer immunoglobulin–like receptor signaling at natural killer cell immunological synapses
por: Treanor, Bebhinn, et al.
Publicado: (2006)

Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma
por: Sato, Yota, et al.
Publicado: (2020)

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
por: Mizugaki, Hidenori, et al.
Publicado: (2016)

Deciphering the killer‐cell immunoglobulin‐like receptor system at super‐resolution for natural killer and T‐cell biology
por: Béziat, Vivien, et al.
Publicado: (2016)

Identification of the ancestral killer immunoglobulin-like receptor gene in primates
por: Sambrook, Jennifer G, et al.
Publicado: (2006)

Human diversity of killer cell immunoglobulin-like receptors and disease
por: Rajalingam, Raja
Publicado: (2011)

Analysis of Killer Immunoglobulin-Like Receptor Genes in Colorectal Cancer
por: Diaz-Peña, Roberto, et al.
Publicado: (2020)

Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver
por: Nakashima, Hiroyuki, et al.
Publicado: (2023)

Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium
por: Nakajima, Masayuki, et al.
Publicado: (2021)

Natural killer cytolytic activity is associated with the expression of killer cell immunoglobulin-like receptors on peripheral lymphocytes in human.
por: Kogure, Toshiaki, et al.
Publicado: (2003)

The effect of interleukin-15 on the expression of killer-cell immunoglobulin-like receptors on peripheral natural killer cells in human.
por: Kogure, Toshiaki, et al.
Publicado: (2002)

Killer immunoglobulin-like receptor genes and heterosexual HIV-1 transmission
por: Merino, Aimee, et al.
Publicado: (2010)

Associations of Killer Cell Immunoglobulin- Like Receptor Genes with Rheumatoid Arthritis
por: Ramírez-De los Santos, S., et al.
Publicado: (2012)

Role of Killer Immunoglobulin-Like Receptor and Ligand Matching in Donor Selection
por: Beksaç, Meral, et al.
Publicado: (2012)

Reproduction, infection and killer-cell immunoglobulin-like receptor haplotype evolution
por: Penman, Bridget S., et al.
Publicado: (2016)

Clostridium difficile Colitis and Neutropenic Fever Associated with Docetaxel Chemotherapy in a Patient with Advanced Extramammary Paget's Disease
por: Nonomura, Yumi, et al.
Publicado: (2012)

Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
por: Ohuchi, Kentaro, et al.
Publicado: (2021)

Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness
por: Segerberg, Filip, et al.
Publicado: (2019)

Cutaquig(®) Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
por: Brownlee, Sydney, et al.
Publicado: (2022)

Different cell imaging methods did not significantly improve immune cell image classification performance
por: Ogawa, Taisaku, et al.
Publicado: (2022)

Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population
por: Bontadini, A, et al.
Publicado: (2006)

Influence of activating and inhibitory killer immunoglobulin-like receptors on predisposition to recurrent miscarriages
por: Moffett, Ashley, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_vkkgrg5a5sv22bactl5npk3ogr